The 2011 HESI Annual Meeting was held June 6-9, 2011 at the Crowne Plaza Old Town Alexandria Hotel in Alexandria, Virginia.
Our annual meeting was an opportunity to learn more about scientific issues of the day from very knowledgeable speakers. It was also an excellent opportunity to meet policy makers and others involved in the identification and resolution of health and environmental issues of concern to the public, scientific community, government agencies, and industry.
To view the meeting program, please click here.
Welcome to HESI Assembly of Members
Dr. Marc Bonnefoi, sanofi aventis
Welcome and Introduction
Dr. B. Bhaskar Gollapudi, The Dow Chemical Company
Reports on Existing HESI Emerging Issues Subcommittees
HESI Subcommittee on Evaluating Causality in Epidemiologic Studies
Dr. A. Robert Schnatter, ExxonMobil Biomedical Sciences, Inc.
New Topic Areas for Consideration By HESI Constituency
Modeling the environmental impact from water withdrawal and disposal across the life cycle of products
Dr. Jennifer Orme-Zavaleta, US Environmental Protection Agency, and Mr. Gert Van Hoof, The Procter & Gamble Company
Frameworks for alternative chemical assessment and selection of safer, sustainable alternatives
Dr. P. Robert Peoples, ACS Green Chemistry Institute
Dr. Pamela Spencer, The Dow Chemical Company, and Dr. Robert Barter, ExxonMobil Biomedical Sciences, Inc.
Human iPS/ES cell technology and its application to toxicology testing, especially focusing on in vitro cardiac function toxicity
Prof. Kenji Yasuda, Tokyo Medical and Dental University
Dr. Atsushi Sanbuissho, Daiichi Sankyo Co., Ltd.
Introduction to Session
Dr. Michael Holsapple, HESI
Animal Models in Vaccine Testing
Overview of animal models in vaccine testing
Dr. Jan-Willem van der Laan, National Institute for Public Health and the Environment
Adjuvants in preventive vaccines: Focus on autoimmunity
Dr. Sarah Gould, sanofi-pasteur
Developmental tox study designs for preventive vaccines: issues and challenges
Dr. Marion Gruber, US Food and Drug Administration
Developmental and Reproductive Toxicology
DART: Assessing risk to conceptus from drugs in semen
Dr. Kary Thompson, Bristol-Myers Squibb Company
DART: The value of juvenile animal studies
Dr. Mark Hurtt, Pfizer, Inc.
Assaying microRNAs in Biofluids for Detection of Drug-Induced Cardiac Injury
Dr. Karol Thompson, US Food and Drug Administration